A mid-stage clinical trial has investors excited about the biotech's future.
News & Analysis: La Jolla Pharmaceutical
LJPC earnings call for the period ending December 31, 2018.
The company provided preliminary operating results for 2018 and expectations for the year ahead.
Shares drop off after the company reports second-quarter results that left investors wanting more.
The market soared, but these stocks got left behind. Find out why.
The FDA surprised the biopharmaceutical with good news today.
The company's making progress toward an FDA decision on its lead drug candidate, but that's not enough to keep investors happy.
Shares jump after the company reports that the results from its ATHOS-3 study will be published in the New England Journal of Medicine.
The release of upbeat data from an important phase 3 trial has investors cheering.
The stock market may be crashing, but these three biotech stocks couldn't care less.